Literature DB >> 10388747

Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain.

V A Kuznetsov1, R K Puri.   

Abstract

Interleukin-13 (IL-13) is a pleiotropic cytokine that controls growth, differentiation, and apoptosis of immune and tumor cells. To understand the mechanisms of interaction between IL-13 and IL-13 receptors (IL-13R), and the role of the IL-2 receptor common gamma chain (gammac) in IL-13 binding and processing, we have examined IL-13 binding kinetics, dissociation/shedding, and internalization in renal cell carcinoma (RCC) cell lines. We observed a new phenomena in that the apparent rate of association, but not the dissociation, was strongly related to IL-13 concentration. We also observed cooperativity phenomena in IL-13 and IL-13R interaction in control RCC (MLneo) cells, but not in cells transfected with gammac chain (MLgammac). The number of IL-13 binding sites, the effective rate of ligand association, and the dissociation rate constants were reduced in gammac-transfected cells compared to control RCC cells. Two forms of IL-13R were detected in these cell lines, which differed in the kinetics of endocytosis and dissociation/exocytosis. Only a small fraction of bound receptors (14-24%) was rapidly internalized and the same fraction of the ligand-receptor complexes was shed and/or dissociated. The expression of gammac chain did not change any of these processes. A two independent high-affinity and moderate-affinity receptor model fit the kinetic observations in gammac-transfected cells. However, in control cells, the binding kinetics were more complicated. A mathematical model that fit a set of kinetic and steady state data in control cells was selected from a set of possible models. This best-fit model predicts that 1) two different IL-13R are expressed on the cell membrane, 2) a minor fraction of IL-13R exist as microclusters (homodimers and/or heterodimers) without exogenous IL-13, 3) high morphological complexity of the gammac-negative control cell membrane affects the cooperativity phenomena of IL-13 binding, and 4) a large number of co-receptor molecules is present, which helps keep the ligand on the cell surface for a long period of time after fast IL-13 binding and provides a negative control for ligand binding via production of the high affinity inhibitor bound to IL-13. Our data demonstrate that gammac exerts dramatic changes in the kinetic mechanisms of IL-13 binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388747      PMCID: PMC1300319          DOI: 10.1016/S0006-3495(99)76879-7

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  39 in total

1.  Aggregation of IgE-receptor complexes on rat basophilic leukemia cells does not change the intrinsic affinity but can alter the kinetics of the ligand-IgE interaction.

Authors:  R G Posner; B Lee; D H Conrad; D Holowka; B Baird; B Goldstein
Journal:  Biochemistry       Date:  1992-06-16       Impact factor: 3.162

2.  Evidence for p55-p75 heterodimers in the absence of IL-2 from Scatchard plot analysis.

Authors:  B Goldstein; D Jones; I G Kevrekidis; A S Perelson
Journal:  Int Immunol       Date:  1992-01       Impact factor: 4.823

3.  Cell surfaces and fractal dimensions.

Authors:  K M Keough; P Hyam; D A Pink; B Quinn
Journal:  J Microsc       Date:  1991-07       Impact factor: 1.758

4.  The distribution of IL-13 receptor alpha1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4.

Authors:  P Graber; D Gretener; S Herren; J P Aubry; G Elson; J Poudrier; S Lecoanet-Henchoz; S Alouani; C Losberger; J Y Bonnefoy; M H Kosco-Vilbois; J F Gauchat
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

5.  Computer analysis of receptor-mediated endocytosis and exocytosis mechanisms: two pathways for the processing of TCR-CD3 receptor complexes of T lymphocytes.

Authors:  V A Kuznetsov
Journal:  Biomed Sci       Date:  1990

6.  Physics of chemoreception.

Authors:  H C Berg; E M Purcell
Journal:  Biophys J       Date:  1977-11       Impact factor: 4.033

7.  Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody.

Authors:  B Goldstein; R G Posner; D C Torney; J Erickson; D Holowka; B Baird
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

8.  The effect of receptor density on the forward rate constant for binding of ligands to cell surface receptors.

Authors:  J Erickson; B Goldstein; D Holowka; B Baird
Journal:  Biophys J       Date:  1987-10       Impact factor: 4.033

9.  Binding, internalization, and intracellular processing of proteins interacting with recycling receptors. A kinetic analysis.

Authors:  Z Bajzer; A C Myers; S Vuk-Pavlović
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

10.  Characterization of the human B cell stimulatory factor 1 receptor.

Authors:  L S Park; D Friend; H M Sassenfeld; D L Urdal
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

2.  Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

Authors:  Bharat H Joshi; Rada A Puri; Pamela Leland; Frederick Varricchio; Ghanshyam Gupta; Mehmet Kocak; Richard J Gilbertson; Raj K Puri
Journal:  Neuro Oncol       Date:  2008-04-22       Impact factor: 12.300

Review 3.  The gene encoding interleukin-13: a susceptibility locus for asthma and related traits.

Authors:  M Wills-Karp
Journal:  Respir Res       Date:  2000-07-17

4.  Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix.

Authors:  Benjamin J Umlauf; Paul A Clark; Jason M Lajoie; Julia V Georgieva; Samantha Bremner; Brantley R Herrin; John S Kuo; Eric V Shusta
Journal:  Sci Adv       Date:  2019-05-15       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.